Reading this on a mobile device? Try our optimized mobile version here:

November 2, 2012
Sign upForwardArchiveAdvertise
News for nuclear medicine and molecular imaging professionals
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at

  Top Story 
  Clinical News & Research 
  • PET helps modify treatment for Merkel cell carcinoma
    FDG-PET imaging helped modify treatment or treatment plans in about 33% of Merkel cell carcinoma patients, according to a study presented at a radiation oncology meeting. Researcher Dr. Michael MacManus of Australia said the study reached its primary endpoint -- that PET would have at least a 10% high impact or a 25% high or medium impact on patient treatment. "The implication of this study is that these tests not only determine prognosis of disease but will impact how we treat it," said Dr. John Ashman of the Mayo Clinic in Scottsdale, Ariz., who was a co-moderator of a session at the meeting. MedPage Today(free registration) (11/1) LinkedInFacebookTwitterEmail this Story
  Industry Report 
  • Report: Global nuclear medicine market to reach $2.46B by 2018
    A report from Global Industry Analysts projects that the global nuclear medicine market will be valued at $2.46 billion by 2018. The major drivers for this growth include more cases of neurological and cardiac diseases, advances in nuclear medicine devices and increased adoption of hybrid modalities such as SPECT/CT and PET/CT, the report said. PR Web/News release (11/1) LinkedInFacebookTwitterEmail this Story
  News from the Field 
  • Report: VNA, PACS market to show significant growth by 2018
    A report from Frost & Sullivan estimates that the vendor-neutral archive market will amount to $210 million by 2018 and the picture archiving and communication systems market will grow to $168.2 million by the same year. Both of those numbers are roughly double where they sit today. This growth will be paralleled by the growth in image data volumes, driven by the increasing imaging patient population and the growth in imaging adoption by clinical entities, Frost & Sullivan experts said. Healthcare IT News (11/1) LinkedInFacebookTwitterEmail this Story
  Health Policy 
  • FDA issues guidance on 510(k) goals for FY 2013 to 2017
    The FDA has released guidance outlining its performance objectives and time frames for the 510(k) clearance process for medical devices in fiscal years 2013 to 2017. The goals, meant to address concerns that the 510(k) process has lagged or become too complex, include shrinking the average time for clearance decisions from 150 days in FY 2012 to 124 days in FY 2017. (Boston) (10/29) LinkedInFacebookTwitterEmail this Story
  • New view at FDA gets treatments to patients faster
    Changes in oncologists' treatment expectations, greater influence and advocacy from patients and scientific discoveries fundamentally changed how the FDA reviews cancer drugs, writes Dr. Patricia Keegan, director of the Division of Oncology Products 2 in the agency's Office of Hematology and Oncology Products. Doctors care less about whether a drug shrinks a tumor than its ability to extend life or prevent metastasis, and independent experts urged the FDA to approve drugs sooner, based on a single efficacy study, she writes. The agency now approves cancer drugs faster so patients can benefit sooner, as exemplified in the area of drugs to treat metastatic cancer, Keegan writes. FDA Voice blog (10/31) LinkedInFacebookTwitterEmail this Story
  Advancing Health Care 
  • Researchers use biomarkers to make clinical trials faster, cheaper
    Hematologist Apostolia Tsimberidou and her team have seen significant patient response in Phase I clinical trials when patients with advanced cancer were grouped according to molecular profile, and she is developing a randomized trial to further test this idea. Testing cancer drugs only in patients with a specific biomarker could save money and time, but targeted drugs have narrower markets, making it more difficult for drugmakers to recoup investments. A program called I-SPY, at the University of California, San Francisco, is matching drugs to breast cancer biomarkers, treating patients prior to surgery and giving drugs that have shown efficacy to more new trial participants. Bloomberg (10/31) LinkedInFacebookTwitterEmail this Story
  From SNMMI 
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

Thinking is the enemy of creativity. It's self-conscious, and anything self-conscious is lousy. You can't try to do things. You simply must do things."
--Ray Bradbury,
American writer

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Account Director:   Meryl Harold   (202) 407-7828
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.®  Legal Information